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Abstract: Lung cancer incidence continues to rise and is the number one cause of cancer death in both men and women worldwide 
with projected 221,130 new cases and 156,940 deaths in the United States in 2011.1 Non-small cell lung cancer (NSCLC) represents 
more than 85% of the cases with most patients having either locally advanced or metastatic disease at the time of initial diagnosis, and 
approximately 60%–70% of them have an adenocarcinoma histologic subtype. In the last three years, we have seen several advances 
in the management of NSCLC, with several factors playing an important role in the treatment decision making process. Maintenance 
therapy has been added to the algorithm of NSCLC management and Pemetrexed has been studied as single agent or in combination 
in this setting with recent studies showing safety and improved progression free survival (PFS) and/or overall survival (OS), still the 
disease for the most part has a dismal outcome. More research work needs to be done to identify which patients truly benefit from these 
approaches, and to whom we should offer maintenance or switch maintenance vs. close observation. 
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Introduction
Lung cancer incidence continues to rise and is the 
number one cause of cancer death in both men and 
women  worldwide  with  a  projected  221,130  new 
cases  and  156,940  deaths  in  the  United  States  in 
2011.1 Non-small cell lung cancer (NSCLC) repre-
sents more than 85% of the cases with most patients 
having either locally advanced or metastatic disease 
at the time of initial diagnosis, and approximately 
60%–70% of them have an adenocarcinoma histo-
logic subtype. Several studies have shown that 4 to 
6 cycles of chemotherapy given as frontline therapy 
offer a survival advantage.2–6 For many decades, the 
standard of care was a “watch and wait” approach 
after initial therapy, and then to offer NSCLC patients 
second-line treatment at progression of disease mean-
while patient continues having a good performance 
status. To date, three agents are well established as 
second-line  treatment  for  lung  cancer:  docetaxel, 
pemetrexed, and erlotinib.
The fact that approximately 40 percent of those 
patients who received first line chemotherapy are eli-
gible for second line treatment starts to question if sec-
ond line should be moved upfront (immediately after 
finishing 4 or 6 cycles of induction therapy). There 
were some attempts to prove this concept; however, 
the side effects of conventional chemotherapies out-
weighed their benefits without a survival advantage. 
The advent of more tolerable drugs with a better tox-
icity profile and clinical efficacy such as pemetrexed 
and  erlotinib  caught  the  interest  of  researchers  to 
revisit the issue of maintenance therapy in NSCLC 
patients. Thus, two large randomized clinical trials 
were developed. The first one included pemetrexed 
as maintenance therapy for patients who had received 
4 cycles of platinum-based doublets (none of them 
included pemetrexed) and attained stable disease or 
any  objective  response  (JMEN  trial).7  The  second 
trial known as SATURN trial used erlotinib as main-
tenance therapy with similar inclusion criteria dur-
ing the randomization.8 Because neither JMEN nor 
SATURN used pemetrexed or erlotinib during the ini-
tial therapy, the term “switch maintenance” has been 
coined to differentiate them from a truly maintenance 
therapy in which patient is kept on the same therapeu-
tic agent received during the initial therapy. The later 
is the case for studies such as ECOG 4599, FLEX, 
and  PARAMOUNT  in  which  maintenance  therapy 
involved single agent bevacizumab, cetuximab, and 
pemetrexed, respectively.9–11
ECOG 4599, FLEX, JMEN, and SATURN clini-
cal trials met their primary endpoints, and all of them 
improved overall survival (OS). Nowadays, mainte-
nance or switch maintenance are options that medi-
cal oncologists should discuss with their patients. The 
National Comprehensive Cancer Network recognizes 
bevacizumab, pemetrexed, erlotinib, and cetuximab as 
maintenance or switch maintenance (depending on the 
case) agents with category 1 or 2A designation. Other 
agents like gemcitabine and docetaxel have also been 
studied  for  the  possibility  of  maintenance  use.12–14 
Although  there  were  improvements  in  progression-
free survival (PFS), no significant effect on OS was 
observed. In this article, we will discuss in depth the 
recent developed data as well as ongoing research with 
the antifolate agent known as pemetrexed.
Mechanism of action
Pemetrexed,  a  multitargeted  antifolate  compound, 
works  by  inhibiting  multiple  enzymes  involved  in 
folate metabolism and DNA synthesis. Pemetrexed 
enters cells via the reduced folate carrier, and binds 
to folate receptor-α with a very high affinity, simi-
lar to that of folic acid. Intracellularly, pemetrexed 
is polyglutamated to the active pentaglutamide by a 
reaction  catalyzed  by  folylpolyglutamate  synthase. 
The enzymes inhibited by pemetrexed include thy-
midylate  synthase  (TS),  dihydrofolate  reductase 
(DHFR),  glycinamide  ribonucleotide  formyltrans-
ferase  (GARFT)  and  aminoimidazole  carboxamide 
ribonucleotide  formyltransferase.  Inhibition  of  TS 
results in decreased thymidine production necessary 
for DNA synthesis. In addition, pemetrexed inhibits 
DHFR as well as GARFT which is a folate-dependent 
enzyme involved in purine synthesis (Fig. 1).15–17,27,28 
Contrary  to  methotrexate,  a  potent  antifolate  that 
inhibits mainly DHFR, pemetrexed the major site of 
action is TS.16 The therapeutic benefit of pemetrexed 
in lung cancer when compared to other malignancies 
may also be explained because of the low as baseline 
expression of the TS gene and protein in adenocarci-
nomas of the lung.20
Almost 80% of pemetrexed is bound to plasma 
proteins  and  it  is  rapidly  eliminated  by  urinary 
excretion with a half-life of 3.5 hours. Plasma clear-
ance  is  diminished  in  patients  with  reduced  renal pemetrexed maintenance in advanced NSCLC
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function resulting in an increased systemic exposure; 
pharmacokinetics are not affected by diminished liver 
function due to limited hepatic metabolism.29
Clinical Studies
Background on the use of pemetrexed
Pemetrexed was approved in 2004 as a single agent 
for second line treatment of patients with advanced 
NSCLC (all histologic subtypes) after Hanna et al 
conducted a large randomized phase III trial of pem-
etrexed vs. docetaxel in this clinical setting.18 In this 
study patients received pemetrexed 500 mg/m2 or doc-
etaxel 75 mg/m2 every 21 days. Cycles were repeated 
until disease progression, unacceptable toxicity, or if 
decided by the patient or the investigator. The two 
regimens were found to have analogous efficacy end-
points, including OS (median 8.3 vs. 7.9 months for 
pemetrexed and docetaxel, respectively) and 1-year 
survival (29.7% in both arms). The overall response 
rate (ORR) (9.1% vs. 8.8%) and stable disease (SD) 
rates (45.8% vs. 46.4%) were similar for pemetrexed 
and docetaxel arms, respectively. Other measurements 
such as PFS, median time to response, and duration of 
response were not statistically different among both 
arms. Of note, time to treatment failure was longer 
with pemetrexed (2.3 vs. 2.1 months; P = 0.046).18 
Although comparable in terms of efficacy, grade 3 
and 4 hematologic toxicities had a lower incidence on 
the pemetrexed arm when compared with docetaxel: 
neutropenia  (5.3%  vs.  40.2%),  febrile  neutropenia 
(1.9%  vs.  12.7%)  and  neutropenia  with  infection 
(0.0%  vs.  3.3%);  these  differences  were  obvious 
once the study was amended, and patients received 
supplementation with folic acid and vitamin B-12. 
Anemia and thrombocytopenia rates were similar in 
both arms.   Cullen et al studied a higher dose of peme-
trexed at 900 mg/m2 vs. its standard dose in a random-
ized phase III trial.19 This study found no statistical 
difference in efficacy between the two doses, with a 
median survival of 6.7 vs. 6.9 months, PFS of 2.6 vs. 
2.8 months, ORR of 7.1% vs. 4.3% (P = 0.1616) and 
stable disease (SD) rate 50.6% vs. 53.1% for P500 
and  P900,    respectively.  Conversely,  more  toxicity 
was encountered with P900 dosing.
Peterson et al analyzed all patients enrolled into the 
original phase III study from Hanna and compared the 
outcomes based on histology and treatment delivered. 
This  analysis  revealed  patients  with  nonsquamous 
histology had a longer OS time on pemetrexed than 
on docetaxel (HR, 0.78; P = 0.047), whereas patients 
with squamous histology had a shorter OS time on 
pemetrexed than on docetaxel (HR, 1.56; P = 0.018). 
Similarly, patients with nonsquamous histology had 
a longer PFS time on pemetrexed than on docetaxel 
(HR, 0.82; P = 0.076). As seen with OS, patients with 
squamous histology had a shorter PFS time on pem-
etrexed than on docetaxel (HR, 1.40; P = 0.046).
In  another  landmark  publication,  Scagliotti 
et  al  compared  cisplatin/pemetrexed  vs.  cisplatin/ 
gemcitabine in the first-line setting with a pre-planned 
analyses for efficacy based on histology. In this study, 
1725  chemonaïve  patients  with  Stage  IIIB  or  IV 
NSCLC were randomized to receive either cisplatin 
75 mg/m2 on day 1 plus gemcitabine 1250 mg/m2 on 
days 1 and 8 or cisplatin 75 mg/m2 plus pemetrexed 
at 500 mg/m2 both on day 1 only. Both chemotherapy 
regimens were administered in a 3-week cycle for up 
to six cycles. The OS was identical at 10.3 months for 
both cisplatin/gemcitabine and cisplatin/  pemetrexed, 
but  there  was  a  significant  survival  differences 
according to tumor histologic subtype. Patients with 
adenocarcinoma and large-cell histology had superior 
OS with the cisplatin/pemetrexed arm in comparison 
with cisplatin/gemcitabine (12.6 vs. 10.9 months in 
adenocarcinoma) and 10.4 vs. 6.7 months (in large 
cell histology).21 In this study, cisplatin/gemcitabine 
was  superior  than  cisplatin/pemetrexed  in  patients 
diagnosed  with  squamous  cell  histology  (10.8  vs. 
9.4 months; (P = 0.05). (Table 1). Thus, based on these 
2 studies, pemetrexed found a change in its package 
insert when the US Food and Drug Administration 
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Figure 1. pemetrexed mechanism of action.velez et al
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(FDA)  limited  its  use  for  non-squamous  NSCLC 
histologies only in 2008.
Maintenance pemetrexed  
as single agent
Once  the  pemetrexed  indication  by  the  US  FDA 
was  restricted  to  non-squamous  cell  histology  and 
approved to be used also as first-line therapy, the next 
step was to study this compound in the maintenance 
setting. In this regard, Ciuleanu et al tested this drug 
as maintenance treatment in the JMEN trial.7 In this 
study, patients were treated with 4 cycles of platinum-
based therapy (6 different doublets were used; none 
included  pemetrexed).  Those  patients  who  attained 
complete response (CR), partial response (PR) or SD 
during induction were randomized to continue main-
tenance therapy with either pemetrexed plus best sup-
portive care (BSC) or placebo plus BSC. A total of 
663 patients with stage IIIB/IV NSCLC and ECOG PS 
0–1 were enrolled into this multicenter, randomized, 
placebo-control trial. Patients were randomly assigned 
in a 2:1; patients with squamous and non-squamous 
histology were included with approximately two third 
of patients presenting with the latter. The final results 
of this trial revealed a statistically significant median 
OS in favor of the pemetrexed group in the overall 
population (13.4 vs. 10.6 months; P = 0.012).7 This 
difference was more pronounced for non-squamous 
NSCLC (15.5 vs. 10.3 months; P , 0.0001) (Table 2). 
  Moreover, for patients who had adenocarcinoma his-
tology, the median OS was a striking 16.8 months.7 
  Furthermore,  to  confirm    pemetrexed-histology 
  selectivity,  those  patients  who  had  squamous  cell 
  carcinoma did much better on   placebo than   pemetrexed 
(10.8  vs.  9.9  months).    Treatment-related  adverse 
events  (AEs)  were  more  common  in  those  treated 
with  pemetrexed  when  compared  to  placebo,  with 
fatigue and   neutropenia being the most common side 
effects.  Nonetheless,  the  maintenance  therapy  was 
well   tolerated. The differences found in survival based 
on histologic subtypes in the JMEN trial confirmed 
those from the two large phase III trials previously 
discussed. Based on this study, the US FDA approved 
pemetrexed  as    maintenance  therapy  for  advanced 
  non-squamous NSCLC in 2009.
Nevertheless, JMEN did not answer the question 
if  maintenance  pemetrexed  was  effective  once  the 
patient  has  been  exposed  to  this  compound  in  the 
initial  4  cycles  of  therapy. Thus,  there  was  skepti-
cism among clinicians if continuing pemetrexed after 
4 cycles of cisplatin/pemetrexed can match the results 
from the JMEN study in terms of PFS and OS. Hence, 
the  PARAMOUNT  trial  was  designed  and  in  the 
2011 American Society of Clinical Oncology (ASCO) 
Table 1. Efficacy of pemetrexed in the treatment of NSCLC.
Authors Chemotherapy  
regimen
Overall  
survival
Overall  
response rate
stable  
disease
Progression   
free survival
Hanna et al18 pemetrexed 
vs. 
docetaxel
8.3 months 
vs. 
7.9 months
9.1% 
vs. 
8.8%
45.8% 
vs. 
46.4%
2.9 months 
vs. 
2.9 months
Cullen et al19 High-dose pemetrexed 
vs. 
Standard dose pemetrexed
6.7 months 
vs. 
6.9 months
7.1% 
vs. 
4.3%
50.6% 
vs. 
53.1%
2.6 months 
vs. 
2.8 months
Scagliotti et al21 Cisplatin/pemetrexed 
vs. 
Cisplatin/gemcitabine
10.3 months 
vs. 
10.3 months
30.6% 
vs. 
28.2%
Not reported 4.8 months 
vs. 
5.1 months
Ciuleanu et al7 Maintenance pemetrexed 
vs. 
Best supportive care
13.4 months 
vs. 
10.6 months
6.8% 
vs. 
1.8%
51.7% 
vs. 
33.3%
4.3 months 
vs. 
2.6 months
Table 2. Efficacy measures according to treatment group 
in the JMEN trial (pemetrexed vs. placebo as   maintenance 
therapy).
Outcome value Pemetrexed 
(n = 441)
Placebo 
(n = 222)
P value
response rate  
(% of patients)
6.8 1.8 0.05
Median overall  
survival (months)
13.4 10.6 0.012
Median progression  
free survival (months)
4.3 2.6 ,0.0001pemetrexed maintenance in advanced NSCLC
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meeting, investigators presented the preliminary results 
of this important study.11 The PARAMOUNT trial is a 
phase III randomized double blinded study looking at 
maintenance pemetrexed plus BSC vs. placebo plus 
BSC in patients with advanced non-squamous NSCLC 
after induction with pemetrexed plus cisplatin. A total 
of 939 patients received four cycles of pemetrexed and 
cisplatin every three weeks; those patient who had not 
progressed and who had preserved performance status 
were randomized in a 2:1 ratio to receive either main-
tenance premetrexed plus BSC (n = 359) or placebo 
plus BSC (n = 180). Pemetrexed continuation resulted 
in  a  reduction  in  the  risk  of  progression  of  36% 
(P = 0.00025), median PFS was 4.1 vs. 2.8 months 
in favor of pemetrexed (P = 0.00006) (Table 3) and, 
disease control rate (DCR) was 71.8 vs. 59.6% also 
in favor of pemetrexed arm (P = 0.009). Serious AEs 
were more common in the pemetrexed arm compared 
to the placebo group with 8.9 vs. 2.8%. The rate of dis-
continuation due to AEs was higher in the pemetrexed 
arm than placebo group (5.3% vs. 3.3%).
Maintenance pemetrexed  
in combination with another agent
The safety and efficacy of pemetrexed plus bevaci-
zumab has been evaluated in a phase II study conducted 
by Sandler and colleagues.23 The authors treated 120 
non-squamous NSCLC patients who had unresectable 
or recurrent disease. The patients were randomized to 
receive docetaxel or pemetrexed plus placebo (arm 1), 
docetaxel or pemetrexed plus bevacizumab (arm 2), 
or bevacizumab plus erlotinib (arm 3). AEs prompt-
ing drug discontinuation were greater in the chemo-
therapy containing arms (24% in the   chemotherapy 
alone arm and 28% in the   chemotherapy and bevaci-
zumab arm) compared to 13% in the bevacizumab plus 
  erlotinib arm. The most common non hematologic AE 
was fatigue in 65% of patients. There were no grade 5 
  neutropenias. The median PFS times for chemotherapy 
alone, bevacizumab-chemotherapy, and bevacizumab-
erlotinib were 3.0, 4.8, and 4.4 months, respectively. 
Median OS times were 8.6, 12.6, and 13.7 months for 
the  chemotherapy  alone,  bevacizumab-chemother-
apy,  and  bevacizumab-erlotinib  arms,  whereas  the 
1-year survival rates were 33.1%, 53.8%, and 57.4%, 
respectively. This phase II study suggested that beva-
cizumab enhanced the activity of chemotherapy and 
was safe to use in combination with pemetrexed. Also, 
in another phase II trial, Patel et al studied this com-
bination plus carboplatin during induction phase fol-
lowed by maintenance pemetrexed and bevacizumab.24 
In this trial, 50 patients were enrolled with a median 
follow-up of 13.0 months and a median number of 
treatment cycles of seven (1 to 51). Thirty patients 
(60%)    completed  $six  treatment  cycles,  and  nine 
(18%) completed $18 treatment cycles. Among the 
49 patients assessable for response, the ORR was 55% 
(95% CI, 41% to 69%). Median PFS and OS rates were 
7.8 months and 14.1 months, respectively. Grade 3/4 
hematologic toxicity in up to 8% of patients included 
anemia, neutropenia, and thrombocytopenia. Grade 3/4 
non hematologic toxicities occurred in a small group of 
patients and included proteinuria, venous thrombosis, 
arterial  thrombosis,  fatigue,  infection,  nephrotoxic-
ity, and diverticulitis. There was no grade 3 or greater 
hemorrhagic events or hypertension cases.
Based on the safety data observed with the com-
bination of pemetrexed and bevacizumab as well 
as its efficacy on non-squamous NSCLC histology, 
several clinical trials were launched. Some of them 
have  recently  reported  their  preliminary  results, 
and others are still ongoing. Among these studies, 
AVAPERL1 by Barlesi et al initially reported its 
safety data at the 2011 ASCO meeting.25 Herein, 
the trial is looking at bevacizumab alone or in com-
bination with pemetrexed as maintenance therapy 
after first line treatment with cisplatin, pemetrexed 
and  bevacizumab  in  chemonaive  patients  diag-
nosed  with  metastatic  or  recurrent  NSCLC.  The 
safety analysis reported that most AEs were grade 
1 or 2. The most common grade 3 or more AEs 
were    neutropenia,  embolism,  hypertension,  ane-
mia, fatigue, diarrhea, nausea, vomiting, hyperg-
lycemia,  pneumonia,  and  dyspnea.  Serious  AEs 
included  pneumonia,  dyspnea,  embolism,  pul-
monary embolism, neutropenia, renal failure and 
Table 3. reported progression-free survival and response 
rates from pArAMOUNT trial.
Pemetrexed + Bsc  
(n = 359)
Placebo + Bsc   
(n = 180)
pFS (months) 3.9 (3.0–4.2) 2.6 (2.2–2.9)
response rates  
n (%)*
9 (2.9) 0 (0.6)
Note: *response rates after randomization.velez et al
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nausea (Table 4). In the 2011 European Society of 
Medical Oncology (ESMO) meeting, Dr.   Barlesi 
et  al,  presented  the    preliminary  efficacy  results 
of this trial. Primary endpoint is PFS and second-
ary endpoints are OS, ORR, DCR, and duration of 
response. The study met its primary endpoint by 
reporting a statistically difference in PFS between 
the two groups: 10.2 months (cisplatin/pemetrexed/
bevacizumab    followed  by  maintenance  bevaci-
zumab/pemetrexed) vs. 6.6 months (same induction 
therapy followed by single agent bevacizumab as 
maintenance therapy) (HR: 0.5, P , 0.001).30 From 
the randomization, PFS was 7.4 vs. 3.7 months in 
favor  of  maintenance  pemetrexed/bevacizumab 
(HR: 0.48, P , 0.001). OS is still immature.
Another  very  interesting  trial  which  recently 
completed accrual is the PointBreak study.26 In this 
trial, Patel et al are currently looking into two dif-
ferent treatment approaches; both of them include 
a  maintenance  phase.  This  is  an  open  phase  III 
randomized  clinical  trial.  Patients  with  advanced 
non-squamous NSCLC are randomized to receive 
either 4 cycles of carboplatin/pemetrexed/bevaci-
zumab induction followed by pemetrexed and bev-
acizumab maintenance (as described by Patel et al,   
J Clin Oncol 2009)24 or carboplatin/paclitaxel/beva-
cizumab induction followed by bevacizumab alone 
(as described by Sandler et al, NEJM 2006). The 
primary objective of this study is OS and second-
ary endpoints were response rate, DCR, PFS, and 
time to progressive disease, safety and quality of 
life will also be evaluated.
Conclusion
In the last three years, we have seen several advances 
in the management of NSCLC, and now we have sev-
eral factors playing an important role in the treatment 
decision  making  process.  Maintenance  therapy  has 
been added to the algorithm of NSCLC management. 
Although all these recent studies have improved PFS 
and/or OS, the disease for the most part still have a 
dismal outcome. Some patients do very well while 
other  progress  with  our  best  therapies  and  the  use 
of a clinical biomarker such as histology subtype to 
select treatment. Thus, more research work needs to 
be done to identify which patients truly benefit from 
these approaches, and to whom we should offer main-
tenance or switch maintenance vs. close observation.
Several  predictive  biomarkers  are  still  on  vali-
dation through large phase III clinical trials. Today, 
the  only  predictive  molecular  biomarkers  that  we 
have to personalize our NSCLC therapies are epi-
dermal growth factor receptor (EGFR) mutation and 
the  presence  of  EML4/ALK  mutation.  In  the  case 
of pemetrexed, TS has been proposed as a potential 
predictive biomarker, but its utility in this regard is 
under investigation. There is no question that if we 
are able to predict a major response on the tumor, the 
likelihood that we may impact PFS and OS will also 
be higher. Thus far, histology has become a clinical 
biomarker to select therapy in NSCLC management 
for agents such as pemetrexed (due to its efficacy) 
and bevacizumab (due to safety and efficacy factor). 
But, we can do much better than that, and proofs of it 
are the development of other therapies based on the 
Table 4. Safety data comparing bevacizumab/pemetrexed vs. bevacizumab alone as maintenance therapy. AvApErL1 
Trial.
Bevacizumab  
maintenance  
(n = 110)
Bevacizumab/pemetrexed 
maintenance  
(n = 117)
Number of AE any grade 867 1134
Number and (%) of patients with AE 102 (93%) 110 (94%)
Number of AE grade $3 55 44
Number and (%) of patients with grade $3 AE 38 (35%) 45 (38%)
% of patients with AE by phase
  First line 82 86
  Maintenance 65 72
% of patients with AE by intensity
  Grade 1/2 85/73 90/74
  Grade 3/4 31/4 37/6
  Grade 5 3 2pemetrexed maintenance in advanced NSCLC
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expression of certain tumor markers; a discussion that 
is beyond the scope of this review.
Pemetrexed  has  gone  through  many  changes  in 
the last 3 years since its approval back in 2004. The 
safety profile of this drug has made possible its study 
in the maintenance setting and the possibility to com-
bine it with other efficacious drugs such as bevaci-
zumab in this setting. We are eager to know the final 
results of PARAMOUNT and PointBreak. The latest 
large phase 3 trial reporting a positive outcome is 
AVAPERL1 (ESMO, Stockholm, Sweden, September 
2011). The Eastern Cooperative Oncology Group has 
also joined to this task: to define the best induction 
therapy and maintenance approach for non-squamous 
NSCLC. ECOG 5508 will usecarboplatin/paclitaxel/
bevacizumab (4 cycles) as initial therapy, and then 
patients who attain objective response or stable dis-
ease will be randomized into three arms: pemetrexed 
alone, bevacizumab alone, and the combination of 
these two agents. We hope that altogether will give 
us and our patients a final answer in terms of the best 
initial and best maintenance approach for advanced 
non-squamous NSCLC patients.
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